Centchroman--a non-steroidal anti-cancer agent for advanced breast cancer: phase-II study.

Abstract

Treatment with Centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-p-(beta-pyrrolidinoethoxy) phenyl-7-methoxy chroman) has been evaluated in 4 male and 75 female patients with advanced breast cancer. The overall response rate, including both male and female cases, was 40.5%. Among the female patients, the overall response rate was 38.7%. The median duration of response was 6 months. One of the 4 male patients showed a complete response and 2 showed partial responses. The responses were more marked for bone, pulmonary, soft tissue, skin and lymph-node metastases than for liver metastases.

• Authors: N C Misra, P K Nigam, R Gupta, A K Agarwal, V P Kamboj
• Journal: International journal of cancer (Int J Cancer) Vol. 43 Issue 5 Pg. 781-3 (May 15 1989) ISSN: 0020-7136 [Print] United States
• PMID: 2714882 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Benzopyrans
• Biomarkers, Tumor
• Receptors, Estrogen
• Centchroman

Topics

• Adult
• Aged
• Antineoplastic Agents
• Benzopyrans (therapeutic use)
• Biomarkers, Tumor (analysis)
• Breast Neoplasms (drug therapy)
• Centchroman (adverse effects, therapeutic use)
• Drug Evaluation
• Female
• Humans
• Male
• Middle Aged
• Neoplasm Metastasis
• Prognosis
• Receptors, Estrogen (analysis)